BI-HEX®

High expression biotechnology

The Boehringer Ingelheim High Expression Technology (BI-HEX®) is an established high expression technology platform that facilitates fast-track development of high-quality, high-titer processes for production of biopharmaceuticals from mammalian cell cultures (CHO cells).
 

The integrated state-of-the-art technology platform, BI-HEX®, encompasses:

  • Optimized expression vectors with proprietary genetic elements.
  • Suspension adapted CHO-DG44 host cell line portfolio for improved protein secretion (look also at CONCERT™) and with different glycoprofiles.
  • Proprietary chemically defined media and feed platform and well-characterized down-scale models.
  • Automation and miniaturization platforms for high throughput screening in cell line and purification development (RAPPTor™).
  • DoE-driven process development supported by state-of-the-art process monitoring and Systems Biotechnology approaches. 

The very robust cell lines grow in chemically defined serum-free media from day one. We achieve record specific productivities of up to 100 pg/cell/day and titers up to 8 g/L. Through early integration of analytical methods a fast assessment of product quality is possible. Furthermore, the extended CHO host cell portfolio allows the best product fit—a perfect match for second-generation processes. Your cell line can be generated in as few as seven months.

In total, more than 40 BI-HEX® cell line development programs have been completed and material produced using this method was sufficient to meet the supply requirements for conducting Phase III clinical trials.

Contact Us

Boehringer Ingelheim BioXcellence - Contact Us

Do you have any inquiries, questions or comments? Please get in touch with us.